Enlivex Therapeutics to Host Webinar on August 18
Ticker: ENLV · Form: 6-K · Filed: Aug 14, 2025 · CIK: 1596812
Sentiment: neutral
Topics: corporate-event, investor-relations
Related Tickers: ENLV
TL;DR
Enlivex (ENLV) hosting a webinar Aug 18th for company updates.
AI Summary
Enlivex Therapeutics Ltd. announced on August 14, 2025, that it will host a webinar on August 18, 2025, at 8:00 AM Eastern Time. The webinar will provide an update on the company's progress and strategic initiatives.
Why It Matters
This webinar provides an opportunity for investors and stakeholders to receive direct updates on the company's development and future plans.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a corporate event (webinar) and does not contain significant financial or operational news.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- August 14, 2025 (date) — Announcement Date
- August 18, 2025 (date) — Webinar Date
- 8:00 AM (time) — Webinar Time
FAQ
What is the purpose of the webinar hosted by Enlivex Therapeutics Ltd.?
The webinar is intended to provide an update on the company's progress and strategic initiatives.
When will the webinar hosted by Enlivex Therapeutics Ltd. take place?
The webinar will be hosted on Monday, August 18, 2025, at 8:00 AM Eastern Time.
What is the filing date of this report?
This report was filed on August 14, 2025.
Under which form is Enlivex Therapeutics Ltd. filing this report?
Enlivex Therapeutics Ltd. is filing this report under Form 6-K.
What is the principal executive office address of Enlivex Therapeutics Ltd.?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-08-14 08:42:07
Filing Documents
- ea0253151-6k_enlivex.htm (6-K) — 15KB
- ea025315101ex99-1_enlivex.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-076091.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: August 14, 2025 2